ING N 201: Ad-p53, Ad5CMV-p53, adenoviral p53, INGN 101, p53 gene therapy - Introgen, RPR/INGN 201

BioDrugs

Volumn 17, Issue 3, 2003, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ADENOVIRUS VECTOR; ADVEXIN; CISPLATIN; ORPHAN DRUG; PROTEIN P53; RPR; TAXOID; UNCLASSIFIED DRUG;

ANOREXIA; ARTHRALGIA; ASTHENIA; BLADDER CANCER; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER REGRESSION; CHILL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPNEA; EUROPE; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; GENE DELETION; GENE MUTATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HEADACHE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; HYPOTENSION; INJECTION SITE; LICENSING; LIVER CANCER; LUNG BIOPSY; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NONHUMAN; NORTH AMERICA; OVARY CANCER; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMOTHORAX; PRIORITY JOURNAL; PROSTATE CANCER; PUBLICATION; RESPIRATORY DISTRESS SYNDROME; REVIEW; TACHYCARDIA; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VOMITING; ADENOVIRUS; ANIMAL; GENE THERAPY; GENE VECTOR; GENETICS; MOUSE; NEOPLASM;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0347625437     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Introgen Therapeutics Inc. Introgen's ADVEXIN® receives orphan drug designation from the FDA. Media Release: 20 Feb 2003. Available from URL: http://www.introgen.com
2. Introgen Therapeutics Inc, Board of Regents of the University of Texas System. Important Patent Issued for Introgen's ADVEXIN® cancer therapeutic; claims focus on DNA core of drug. Media Release: 5 Feb 2003. Available from URL: http://www.introgen.com
3. Results of first gene therapy study to demonstrate tumor regression and positive safety profile in head and neck cancer pesented at ASCO. PR Newswire [online]: [3 pages], 19 May 1997. Available from URL: http://www.newspage.com
4. Rhone-Poulenc Rorer. Phase II p53 gene therapy clinical trials show evidence of tumor growth control in head and neck cancer patients. Media Release: [3 pages], 18 May 1999. Available from URL: http://www.rp-rorer.com
5. Swisher S, Roth JA, Komaki R, et al. A phase II trial of adenoviral mediated P53 gene transfer (RPR/INGN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer. 36th Annual Meeting of the American Society of Clinical Oncology 19: 461 (plus poster), 20 May 2000
6. Yver A, Dreiling LK, Mohanty S, et al. Tolerance and safety of RPR/INGN 201, an adeno-viral vector containing a p53 gene, administered intratumorally in 309 patients with advanced cancer enrolled in phase I and II studies world-wide. 36th Annual Meeting of the American Society of Clinical Oncology 19: 460 (plus poster), 20 May 2000
7. Introgen Therapeutics Inc. Introgen's adenoviral vector demonstrates safety in phase II study; biosafety data presented at American Society of Gene Therapy Meeting. Media Release: [2 pages], 1 Jun 2001. Available from URL: http://www.introgen.com
8. Introgen Therapeutics Inc. Introgen presents new safety information for INGN 201 in cancer. Media Release: [2 pages], 17 Dec 2001. Available from URL: http://www.introgen.com
9. Hao D, Rowinsky EK, Smetzer LA, et al. A phase I and pharmacokinetic study of intravenous p53 gene therapy with RPR/INGN-201 in patients with advanced cancer. 37th Annual Meeting of the American Society of Clinical Oncology 20: 262, Part 1, 12 May 2001
10. Nemunaitis J, Goodwin WJ, Bier-Laning C, et al. Intratumoral adenoviral-mediated p53 gene therapy is associated with a survival advantage in recurrent squamous cell cancer of the head and neck based on a dose response model using phase 2 data. 93rd Annual Meeting of the American Association for Cancer Research - Supplement: 83 (plus poster), 6 Apr 2002
11. Introgen Therapeutics Inc. Introgen Therapeutics ADVEXIN® gene therapeutic experience highlighted at international p53 meeting. Media Release: 25 Jun 2002. Available from URL: http://www.introgen.com
12. Bacchetti S, Graham FL. Inhibition of cell proliferation by an adenovirus vector expressing the human wild type-p53 protein. International Journal of Oncology 1993 Nov; 3: 781-788
13. Clayman GL, El-Naggar AK, Roth JA, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Research 1995 Jan; 55: 1-6
14. Harris MP, Sutjipto S, Wills KN, et al. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Therapy 1996 Mar-Apr; 3: 121-130
15. Yoo GH, Washington J, Oliver J, et al. The effects of exogenous p53 overexpression on HPV-immortalized and carcinogen transformed oral keratinocytes. Cancer 2002 Jan; 94: 159-166
16. Clayman GL, El-Naggar AK, Merritt J. Adenovires-mediated p53 gene transfer in a phase I trial of patients with advanced recurrent head and neck squamous carcinoma. 33rd Annual Meeting of the American Society of Clinical Oncology: 383, 17 May 1997
17. Merritt JA, Clayman G, Schwisher S. Clinical gene therapy strategies: phase I/II results with adenoviral P53 (INGN 201) gene transfer in advanced head and neck and non small cell lung cancers. 3rd European Conference on Gene Therapy of Cancer: 175, 11 Sep 1997
18. Bier-Laning CM, VanEcho D, Yver A. A phase II multi-center study of AD5CMV-P53 administered intratumorally to patients with recurrent head and neck cancer. 35th Annual Meeting of the American Society of Clinical Oncology 18: 444, 15 May 1999
19. Introgen Therapeutics Inc. Introgen's ADVEXIN® therapy demonstrates survival advantage in patients with advanced cancer. Media Release: 13 Dec 2002. Available from URL: http://www.introgen.com
20. Gene therapy experiment works in lung cancer-study. Media Release: [2 pages], 6 May 1999
21. Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. Journal of Clinical Oncology 2000 Feb; 18: 609-622
22. Introgen Therapeutics Inc. Lung cancer patient reaches five-year survival mark after treatment with Introgen's ADVEXIN® gene drug therapy. Media Release: 2 Jul 2002. Available from URL: http://www.introgen.com
23. Introgen Therapeutics Inc. Introgen Therapeutics reports progress in gene therapy studies at annual ASCO meeting - gene therapy can be combined with radiation therapy and may improve local. Media Release: [4 pages], 22 May 2000. Available from URL: http://www.introgen.com
24. Swisher S, Roth J, Komaki R, et al. Induction of pro-apoptotic mediators and tumor regression following intratumoral delivery of adenoviral p53 and radiation therapy in patients with non-small cell lung cancer. 37th Annual Meeting of the American Society of Clinical Oncology 20: 257 (plus poster), Part 1, 12 May 2001
25. Introgen Therapeutics Inc. Introgen's ADVEXIN® combined with radiation well tolerated and shows tumor regression in phase 2 lung cancer study. Media Release: 14 Jan 2003. Available from URL: http://www.introgen.com